Immunai decloaks with $20M in seed funding to map immune system with machine learning

The company, led by an ex-Palantir engineer and a former Harvard postdoctoral researcher, has developed machine learning algorithms to identify nuances in cells, mechanisms of action and biomarkers that could aid immunotherapy and cell therapy development.

Leave a Reply